1032008-64-2

Upstream product

• 36603-49-3 4-(tetrahydropyran-2'-yloxy)-1-bromobenzene 
• 103628-22-4 1--2-phenyl-butan-1-one 

Downstream Products

• 103628-16-6 Z-1-<4-(2-chloroethoxy)phenyl>-1-(4-hydroxyphenyl)-2-phenyl-1-butene 
• 119757-57-2 (E,Z)-1-<4-(2-chloroethoxy)phenyl>-1-(4-hydroxyphenyl)-2-phenyl-1-butene 

Relevant academic research and scientific papers

Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder

Protein kinase C (PKC) plays a major role in regulation of both pre and postsynaptic neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. Tamoxifen, a widely used breast cancer drug is known to inhibit PKC and demonstrate antimanic properties in human. We describe herein the synthesis of endoxifen, a tamoxifen active metabolite and compared its PKC inhibitory activity with that of tamoxifen. Endoxifen exhibited fourfold higher potency compared to tamoxifen.

ENDOXIFEN METHODS AND COMPOSITIONS

The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast